Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 9;13(1):1858002.
doi: 10.1080/20002297.2020.1858002.

Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19

Affiliations

Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19

Paulo H Braz-Silva et al. J Oral Microbiol. .

Abstract

Background: SARS-CoV-2 quickly spreads in the worldwide population, imposing social restrictions to control the infection, being the massive testing another essential strategy to break the chain of transmission. Aim: To compare the performance of at-home self-collected samples - saliva and combined nasal-oropharyngeal swabs (NOP) - for SARS-CoV-2 detection in a telemedicine platform for COVID-19 surveillance. Material and methods: We analyzed 201 patients who met the criteria of suspected COVID-19. NOP sampling was combined (nostrils and oropharynx) and saliva collected using a cotton pad device. Detection of SARS-COV-2 was performed by using the Altona RealStar® SARS-CoV-2 RT-PCR Kit 1.0. Results: There was an overall significant agreement (κ coefficient value of 0.58) between saliva and NOP. Considering results in either sample, 70 patients positive for SARS-CoV-2 were identified, with 52/70 being positive in NOP and 55/70 in saliva. This corresponds to sensitivities of 74.2% (95% CI; 63.7% to 83.1%) for NOP and 78.6% (95% CI; 67.6% to 86.6%) for saliva. Conclusion: Our data show the feasibility of using at-home self-collected samples (especially saliva), as an adequate alternative for SARS-CoV-2 detection. This new approach of testing can be useful to develop strategies for COVID-19 surveillance and for guiding public health decisions.

Keywords: PCR; Saliva; coronavirus; infection control; primary health care; telemedicine.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
Comparison of RT-PCR cycle thresholds between naso-oropharyngeal and saliva samples in 37 patients with positive results in both samples. The coefficients of the regression lines are 0.79 (P < 0.001) for gene E and 0.74 (P = 0.002) for gene S.
Figure 2.
Figure 2.
(a/b) – Violin plots showing the distribution of cycle thresholds in nasal-oropharyngeal swabs (NOP) and saliva samples for the two genes (E and S) amplified by RT-PCR. Boxplots shows median, interquartile range and range as standard. Analysis of the 37 patients with positive results in both sample types by comparing the distributions of cycle thresholds between NOP and saliva samples. Paired Wilcoxon’s rank-sum test was used, in which P-values were <0.001 for genes E and S. (c/d) – Distribution of SARS-CoV-2 RT-PCR cycle thresholds in the 52 positive nasal-oropharyngeal swabs (NOP) samples stratified by RT-PCR results in saliva (NOP+/saliva- versus NOP+/saliva+). Boxplots shows median, interquartile range and range as standard. Distributions were compared by using paired Wilcoxon’s rank-sum test, in which P-values were 0.21 and 0.35 for genes E and S, respectively
Figure 3.
Figure 3.
Relationship between illness course (i.e. time elapsed between symptom onset and sample collection) and cycle threshold values for nasal-oropharyngeal swabs (NOP) (left-hand panels) and saliva samples (right-hand panels). In the NOP samples, the regression coefficients for cycle threshold (delay of log2-days) for genes E and S were 0.5 (P = 0.72) and 1.1 (P = 0.42), respectively; the regression coefficients for saliva samples were 0.04 (P = 0.98) and −0.26 (P = 0.87) for genes E and S, respectively

References

    1. Landry ML, Criscuolo J, Peaper DR.. Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients. J Clin Virol. 2020;130:104567. - PMC - PubMed
    1. Yokota I, Shane PY, Okada K, et al. Mass screening of asymptomatic persons for SARS-CoV-2 using saliva. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa1388 - DOI - PMC - PubMed
    1. Ott IM, Strine MS, Watkins AE, et al. Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices. medRxiv. 2020. DOI:10.1101/2020.08.03.20165233 - DOI
    1. Hall EW, Luisi N, Zlotorzynska M, et al. Willingness to use home collection methods to provide specimens for SARS-CoV-2/COVID-19 research: survey study. J Med Internet Res. 2020;22:e19471. - PMC - PubMed
    1. Valentine-Graves M, Hall E, Guest JL, et al. At-home self-collection of saliva, oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: post-collection acceptability of specimen collection process and patient confidence in specimens. PLoS One. 2020;15:e0236775. - PMC - PubMed

LinkOut - more resources